We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and...
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic...
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior...
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized...
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated...
Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic...
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announced that it has received approval To...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1 | -3.300330033 | 3.03 | 3.19 | 2.8 | 3626 | 3.01095191 | CS |
4 | -1.05 | -26.3819095477 | 3.98 | 4.08 | 2.8 | 6920 | 3.51260159 | CS |
12 | -2.3 | -43.9770554493 | 5.23 | 5.79 | 2.8 | 9502 | 3.82908059 | CS |
26 | -3.68 | -55.6732223903 | 6.61 | 8 | 2.8 | 6952 | 4.70451737 | CS |
52 | -6.58 | -69.1903259727 | 9.51 | 10.29 | 2.8 | 5607 | 6.23471435 | CS |
156 | -7.91 | -72.9704797048 | 10.84 | 15.05 | 2.8 | 7494 | 8.20036107 | CS |
260 | -7.91 | -72.9704797048 | 10.84 | 15.05 | 2.8 | 7494 | 8.20036107 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions